S&P TSX Capped Composite...

US Dollar vs CAD

Trade smarter, not harder: Unleash your inner pro with our toolkit and live discussions.

Get Started

DRUG Bright Minds Biosciences Inc

41.01

0.19 (0.47%)

Feb 07 2025 - Closed

Delayed by 15 minutes

Form D - Notice of Exempt Offering of Securities

Bright Minds Biosciences (NASDAQ:DRUG)
Historical Stock Chart
From Jan 2025 to Feb 2025

Click Here for more Bright Minds Biosciences Charts.

Bright Minds Biosciences (NASDAQ:DRUG)
Historical Stock Chart
From Feb 2024 to Feb 2025

Click Here for more Bright Minds Biosciences Charts.

Bright Minds Biosciences Inc News

Form F-3 - Registration statement by foreign private issuers
Wednesday 5 February 2025 (4 days ago) • Edgar (US Regulatory)

Bright Minds Biosciences Appoints Pharmaceutical Leader, Stephen Collins, M.D., Ph.D., as Chief Medical Officer
Tuesday 7 January 2025 (1 month ago) • GlobeNewswire Inc.

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]
Thursday 21 November 2024 (3 months ago) • Edgar (US Regulatory)

Bright Minds Biosciences to Present Data at the American Epilepsy Society 2024 Annual Meeting
Thursday 21 November 2024 (3 months ago) • GlobeNewswire Inc.

Form D - Notice of Exempt Offering of Securities
Tuesday 19 November 2024 (3 months ago) • Edgar (US Regulatory)

Form SC 13D/A - General Statement of Acquisition of Beneficial Ownership: [Amend]
Tuesday 5 November 2024 (3 months ago) • Edgar (US Regulatory)

Form SC 13D/A - General Statement of Acquisition of Beneficial Ownership: [Amend]
Tuesday 5 November 2024 (3 months ago) • Edgar (US Regulatory)

Bright Minds Biosciences Closes US$35 Million Non-Brokered Private Placement
Monday 4 November 2024 (3 months ago) • GlobeNewswire Inc.

Form SC 13G - Statement of Beneficial Ownership by Certain Investors
Friday 25 October 2024 (4 months ago) • Edgar (US Regulatory)

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]
Monday 21 October 2024 (4 months ago) • Edgar (US Regulatory)

Bright Minds Biosciences and Firefly Neuroscience to Collaborate After the BREAKTHROUGH Study: A Phase 2 Trial of BMB-101 in Absence Epilepsy and Developmental Epileptic Encephalopathy for Full Analysis of EEG Data
Monday 21 October 2024 (4 months ago) • GlobeNewswire Inc.

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]
Friday 18 October 2024 (4 months ago) • Edgar (US Regulatory)

More Bright Minds Biosciences Inc News Articles

Kraig Biocraft Laborator... (QB)

Voip Pal Com (QB)

North Bay Resources (PK)

UAV Corpoation (PK)

Intergrated Cannabis Sol... (PK)

Asia Broadband (PK)

Lightwave Logic

Accredited Solutions (PK)

Bell Buckle (PK)

Liquidmetal Technologies (QB)

Delayed Upgrade Clock

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions